WBR0509: Difference between revisions
Jump to navigation
Jump to search
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
{{WBRQuestion | {{WBRQuestion | ||
|ExamType=USMLE Step 1 | |ExamType=USMLE Step 1 | ||
|MainCategory=Pharmacology | |MainCategory=Pharmacology | ||
| Line 22: | Line 21: | ||
|SubCategory=Reproductive | |SubCategory=Reproductive | ||
|Prompt=A 31-year-old man presents to the dermatology clinic for hair loss. The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex. He also explains that he has a strong family history of androgenic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful. You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug? | |Prompt=A 31-year-old man presents to the dermatology clinic for hair loss. The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex. He also explains that he has a strong family history of androgenic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful. You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug? | ||
|AnswerA=Phosphodiesterase 5 (PDE5) inhibitor | |AnswerA=Phosphodiesterase 5 (PDE5) inhibitor | ||
|AnswerAExp=Sildenafil, tadalafil - erectile dysfunction | |AnswerAExp=Sildenafil, tadalafil - erectile dysfunction | ||
| Line 33: | Line 31: | ||
|AnswerE=Selective inhibitior of 5-alpha-reductase | |AnswerE=Selective inhibitior of 5-alpha-reductase | ||
|AnswerEExp=finasteride | |AnswerEExp=finasteride | ||
|RightAnswer=E | |RightAnswer=E | ||
|Approved=No | |Approved=No | ||
}} | }} | ||
Revision as of 14:02, 16 September 2014
| Author | PageAuthor:: |
|---|---|
| Exam Type | ExamType::USMLE Step 1 |
| Main Category | MainCategory::Pharmacology |
| Sub Category | SubCategory::Reproductive |
| Prompt | [[Prompt::A 31-year-old man presents to the dermatology clinic for hair loss. The patient reports progressive hairline regression and hair loss mainly localized above the temples and at the vertex. He also explains that he has a strong family history of androgenic alopecia, and cannot stand the idea of going completely bald. The patient has tried many topical products intended for hair loss, which have not been very helpful. You consider using an agent that is also approved for the treatment of benign prostatic hyperplasia. Which of the following is the most likely mechanism of action of this drug?]] |
| Answer A | AnswerA::Phosphodiesterase 5 (PDE5) inhibitor |
| Answer A Explanation | AnswerAExp::Sildenafil, tadalafil - erectile dysfunction |
| Answer B | AnswerB::Competitive inhibitor of testosterone binding at androgen receptors |
| Answer B Explanation | AnswerBExp::flutamide - Nonsteroidal antiandrogen - Prostate Cancer |
| Answer C | AnswerC::Aromatase inhibitor |
| Answer C Explanation | AnswerCExp::exemestane - Breast Cancer |
| Answer D | AnswerD::Agonist of luteinizing hormone-releasing hormone (LHRH) |
| Answer D Explanation | AnswerDExp::leuprolide - Prostate Cancer - Endometriosis - Leiomyoma |
| Answer E | AnswerE::Selective inhibitior of 5-alpha-reductase |
| Answer E Explanation | AnswerEExp::finasteride |
| Right Answer | RightAnswer::E |
| Explanation | [[Explanation:: Educational Objective: |
| Approved | Approved::No |
| Keyword | |
| Linked Question | Linked:: |
| Order in Linked Questions | LinkedOrder:: |